281 related articles for article (PubMed ID: 18070979)
1. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.
Andes D; Diekema DJ; Pfaller MA; Prince RA; Marchillo K; Ashbeck J; Hou J
Antimicrob Agents Chemother; 2008 Feb; 52(2):539-50. PubMed ID: 18070979
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis.
Andes D; Marchillo K; Conklin R; Krishna G; Ezzet F; Cacciapuoti A; Loebenberg D
Antimicrob Agents Chemother; 2004 Jan; 48(1):137-42. PubMed ID: 14693531
[TBL] [Abstract][Full Text] [Related]
3. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.
Andes DR; Diekema DJ; Pfaller MA; Marchillo K; Bohrmueller J
Antimicrob Agents Chemother; 2008 Oct; 52(10):3497-503. PubMed ID: 18625768
[TBL] [Abstract][Full Text] [Related]
4. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model.
Andes D; Marchillo K; Stamstad T; Conklin R
Antimicrob Agents Chemother; 2003 Apr; 47(4):1193-9. PubMed ID: 12654646
[TBL] [Abstract][Full Text] [Related]
5. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.
Andes D; Diekema DJ; Pfaller MA; Bohrmuller J; Marchillo K; Lepak A
Antimicrob Agents Chemother; 2010 Jun; 54(6):2497-506. PubMed ID: 20385855
[TBL] [Abstract][Full Text] [Related]
6. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.
Andes D; Marchillo K; Stamstad T; Conklin R
Antimicrob Agents Chemother; 2003 Oct; 47(10):3165-9. PubMed ID: 14506026
[TBL] [Abstract][Full Text] [Related]
7. Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.
Lepak AJ; Marchillo K; VanHecker J; Diekema D; Andes DR
Antimicrob Agents Chemother; 2013 Nov; 57(11):5642-8. PubMed ID: 24002092
[TBL] [Abstract][Full Text] [Related]
8. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.
Andes D; van Ogtrop M
Antimicrob Agents Chemother; 2000 Apr; 44(4):938-42. PubMed ID: 10722494
[TBL] [Abstract][Full Text] [Related]
9.
Zhao M; Lepak AJ; VanScoy B; Bader JC; Marchillo K; Vanhecker J; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378706
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design.
Lepak AJ; Zhao M; VanScoy B; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203480
[TBL] [Abstract][Full Text] [Related]
11. Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model.
Lepak AJ; Zhao M; Andes DR
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481440
[TBL] [Abstract][Full Text] [Related]
12. Echinocandin antifungal drugs in fungal infections: a comparison.
Chen SC; Slavin MA; Sorrell TC
Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model.
Andes D; Stamsted T; Conklin R
Antimicrob Agents Chemother; 2001 Mar; 45(3):922-6. PubMed ID: 11181381
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
Howard SJ; Livermore J; Sharp A; Goodwin J; Gregson L; Alastruey-Izquierdo A; Perlin DS; Warn PA; Hope WW
Antimicrob Agents Chemother; 2011 Oct; 55(10):4880-7. PubMed ID: 21807969
[TBL] [Abstract][Full Text] [Related]
15. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.
Gumbo T; Drusano GL; Liu W; Ma L; Deziel MR; Drusano MF; Louie A
Antimicrob Agents Chemother; 2006 Nov; 50(11):3695-700. PubMed ID: 16954319
[TBL] [Abstract][Full Text] [Related]
16. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
[TBL] [Abstract][Full Text] [Related]
17. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.
Lepak A; Castanheira M; Diekema D; Pfaller M; Andes D
Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870
[TBL] [Abstract][Full Text] [Related]
18. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
Andes D; Craig WA
Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
[TBL] [Abstract][Full Text] [Related]
19. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
Pfaller MA; Diekema DJ; Ostrosky-Zeichner L; Rex JH; Alexander BD; Andes D; Brown SD; Chaturvedi V; Ghannoum MA; Knapp CC; Sheehan DJ; Walsh TJ
J Clin Microbiol; 2008 Aug; 46(8):2620-9. PubMed ID: 18579718
[TBL] [Abstract][Full Text] [Related]
20. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
Pfaller MA; Diekema DJ; Andes D; Arendrup MC; Brown SD; Lockhart SR; Motyl M; Perlin DS;
Drug Resist Updat; 2011 Jun; 14(3):164-76. PubMed ID: 21353623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
